TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38822391
Drug: Guanfacine (sympatholytic),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (sympatholytic), 6 weeks treatment
Study: 38822391
Drug: Hydrochlorothiazide (diuretic),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (diuretic), 6 weeks treatment
Study: 38822389
Drug: Handheld fluorescence
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Handheld fluorescence imaging device with 5-aminolevulinic acid (5-ALA) administration
Study: 38822943
Drug: IV CM-101
Normalized name: TRAMETES VERSICOLOR STRAIN CM-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV CM-101 2.5 mg/kg
Study: 38822943
Drug: SC CM-101
Normalized name: TRAMETES VERSICOLOR STRAIN CM-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC CM-101 5.0 mg/kg
Study: 38822943
Drug: IV CM-101
Normalized name: TRAMETES VERSICOLOR STRAIN CM-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV CM-101 (0.75 mg/kg, 2.5 mg/kg, 5.0 mg/kg, 10.0 mg/kg)
Study: 38822948
Drug: All four
Normalized name: Jackson's The Original All Fours
Approvals — FDA: no, EMA: no, PMDA: no
Description: All four laser treatments
Study: 38823034
Drug: Cabozantinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (40 mg p.o. daily on days 1-21 of a 21-day cycle) and Pembrolizumab (200 mg i.v. on day 1)
Study: 38823410
Drug: BL-B01D1 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL-B01D1 at 3·0 mg/kg on days 1 and 8 every 3 weeks
Study: 38823410
Drug: BL-B01D1 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL-B01D1 at 6·0 mg/kg on day 1 every 3 weeks
Study: 38824442
Drug: Stepped palliative
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepped palliative care (initial visit within 4 weeks, subsequent visits based on treatment changes or hospitalizations)
Study: 38824658
Drug: molecularly matched
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: molecularly matched therapy
Study: 38824836
Drug: Antibiotic-cement coated
Normalized name: Cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-cement coated plate
Study: 38824872
Drug: Intra-articular steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular steroid injection (ISI)
Study: 38824918
Drug: Hydroxyurea PK
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea PK dosing
Study: 38824918
Drug: Hydroxyurea default
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea default dose
Study: 38824941
Drug: sintilimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sintilimab (200 mg intravenously once every 3 weeks for 12 cycles)
Study: 38824941
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy (gemcitabine and cisplatin induction chemotherapy followed by concurrent cisplatin radiotherapy)
Study: 38825005
Drug: Papaverine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine (80 mg intravenous)
Study: 38825005
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% normal saline solution)
Study: 38825014
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy density food (>3.0 kcal/g)
Study: 38825014
Drug: Medium energy
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium energy density food (1.7-2.0 kcal/g)
Study: 38825014
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy density food (∼1.0 kcal/g)
Study: 38825333
Drug: Specialised mood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialised mood disorder clinic treatment combining evidence-based pharmacological treatment with group psychoeducation
Study: 38825333
Drug: Specialised mood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialised mood disorder clinic treatment
Study: 38825627
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg
Study: 38825627
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine (T-DM1) 3.6 mg/kg
Study: 38825627
Drug: Treatment-emergent adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent adverse events for T-DXd
Study: 38825627
Drug: Treatment-emergent adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent adverse events for T-DM1
Study: 38825688
Drug: Pulmonary endarterectomy
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary endarterectomy (PEA), Balloon pulmonary angioplasty (BPA), and targeted medical therapy
Study: 38825999
Drug: Computer-based biodex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based biodex balance exercise system (BBS) performed twice weekly for 8 weeks
Study: 38826330
Drug: SP-2509 (noncompetitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP-2509 (noncompetitive inhibitor)
Study: 38826570
Drug: Standard step-up
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard step-up conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)
Study: 38826570
Drug: Combination csDMARDs
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination csDMARDs (methotrexate with either sulfasalazine or leflunomide)
Study: 38826570
Drug: Early biologics
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early biologics induction therapy (adalimumab plus methotrexate)
Study: 38827854
Drug: Oral Hydroxychloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Hydroxychloroquine (HC), Azithromycin (AZ), and Oseltamivir (OS)
Study: 38828023
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg HCTZ for four days
Study: 38828023
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg henagliflozin for four days
Study: 38828023
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg HCTZ + 10 mg henagliflozin for four days
Study: 38828023
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (HCTZ + henagliflozin)
Study: 38828109
Drug: Weekly chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly chloroquine prophylaxis (CQ)
Study: 38828563
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose edoxaban regimen (60/30 mg daily)
Study: 38828563
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose edoxaban regimen (30/15 mg daily)
Study: 38828938
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly paclitaxel
Study: 38828958
Drug: IV posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV posaconazole 300 mg q12h and 300 mg q8h for the first two days, followed by 400 mg q24h maintenance
Study: 38828958
Drug: IV posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV posaconazole 300 mg q24h
Study: 38829011
Drug: Dual-IVT strategy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-IVT strategy with tenecteplase 0.25 mg/kg
Study: 38829618
Drug: Remote monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remote monitoring of BP and medication adherence (RM)
Study: 38829618
Drug: Remote monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remote monitoring of BP and medication adherence with social support (SS)
Study: 38829703
Drug: Lademirsen, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lademirsen, dosage and duration not available
Study: 38829882
Drug: EPO-Feeding Program
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO-Feeding Program (four weekly group-based training sessions led by healthcare professionals)
Study: 38830735
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) administered as 1 g at skin incision, followed by an additional 1 g prior to skin closure.
Study: 38830962
Drug: Phase 2
Normalized name: Premphase 28 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2 white kidney bean extract (WKBE HIGH) 1000 mg
Study: 38830962
Drug: Phase 2
Normalized name: Premphase 28 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2 white kidney bean extract (WKBE LOW) 700 mg
Study: 38830992
Drug: satri-cel monotherapy
Normalized name: Obe-cel
DrugBank: Obecabtagene autoleucel (DB17362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: satri-cel monotherapy in 61 patients with standard chemotherapy-refractory gastrointestinal cancers
Study: 38830992
Drug: satri-cel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: satri-cel plus anti-PD-1 therapy in 15 patients with standard chemotherapy-refractory gastrointestinal cancers
Study: 38830992
Drug: satri-cel as
Normalized name: Obe-cel
DrugBank: Obecabtagene autoleucel (DB17362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: satri-cel as sequential treatment after first-line therapy in five patients with gastrointestinal cancers
Study: 38830992
Drug: satri-cel monotherapy
Normalized name: Obe-cel
DrugBank: Obecabtagene autoleucel (DB17362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: satri-cel monotherapy in two patients with anti-CLDN18.2 monoclonal antibody-refractory gastric cancer
Study: 38831415
Drug: Integrated MOUD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated MOUD and HIV treatment/prevention through a mobile unit
Study: 38832837
Drug: Dexmedetomidine infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusions
Study: 38832837
Drug: Continuous infusions
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusions of opioids
Study: 38832837
Drug: Continuous infusions
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusions of ketamine
Study: 38832949
Drug: Oral THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral THC (10 mg)
Study: 38832995
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of adenosine
Study: 38833144
Drug: IVL3001 (12-36
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVL3001 (12-36 mg)
Study: 38833144
Drug: IVL3001 (12-36
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVL3001 (12-36 mg) every 4 weeks
Study: 38833311
Drug: Olaparib treatment
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib treatment
Study: 38833360
Drug: Successful tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Successful tapering of immunosuppressants (IS)
Study: 38833442
Drug: Inhaled xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled xenon during targeted temperature management (TTM) at 33°C for 24 hours
Study: 38833560
Drug: Epinephrine dosing
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine dosing intervals less than 3 minutes
Study: 38833590
Drug: naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 500 mg twice daily for 10 days
Study: 38833643
Drug: Everolimus +
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus + Endocrine Therapy (ET) (10 mg orally once daily for 1 year)
Study: 38833658
Drug: Lenvatinib 20
Normalized name: LENVATINIB 20MG DAILY DOSE PACK,10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 20 mg orally once daily plus pembrolizumab 400 mg intravenously once every 6 weeks
Study: 38833971
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg/kg intravenously every 2 weeks)
Study: 38834087
Drug: Mitazalimab 900
Normalized name: Mitazalimab
DrugBank: Mitazalimab (DB15225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitazalimab 900 μg/kg with mFOLFIRINOX
Study: 38834087
Drug: Mitazalimab 450
Normalized name: Mitazalimab
DrugBank: Mitazalimab (DB15225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitazalimab 450 μg/kg with mFOLFIRINOX
Study: 38834319
Drug: Postnatal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postnatal administration of allogeneic expanded human first trimester fetal liver MSCs (BOOST cells)
Study: 38834319
Drug: Prenatal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal and postnatal administration of allogeneic expanded human first trimester fetal liver MSCs (BOOST cells)
Study: 38834399
Drug: Selinexor maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor maintenance therapy
Study: 38834399
Drug: Selinexor maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor maintenance therapy (TP53wt/pMMR EC)
Study: 38834399
Drug: Selinexor maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor maintenance therapy (TP53wt/dMMR EC)
Study: 38834432
Drug: HRIG (0.133
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRIG (0.133 mL/kg)
Study: 38834744
Drug: Preoperative chemoradiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiotherapy (CRT) followed by nivolumab (240 mg) and surgery
Study: 38834776
Drug: Personalized bacteriophage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized bacteriophage therapy (BT)
Study: 38834776
Drug: Personalized bacteriophage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized bacteriophage therapy (BT) with concomitant antibiotics
Study: 38835146
Drug: Digitally delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitally delivered treatment comprising exercise and patient education
Study: 38837133
Drug: Skill-oriented, material-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skill-oriented, material-based cognitive behavioral therapy (SEKT)
Study: 38837133
Drug: Supportive, patient-centered,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive, patient-centered, emotion-focused therapy (FEST)
Study: 38837144
Drug: Abrocitinib, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrocitinib, 200 mg, by mouth once daily for 12 weeks
Study: 38837707
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) levels ≤500 ng/ml
Study: 38837707
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) levels ≤200 ng/ml
Study: 38837825
Drug: Bronchodilator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator therapy (specific medication not mentioned), administered twice daily for 12 weeks.
Study: 38837825
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving placebo treatment for 12 weeks.
Study: 38837864
Drug: Weight-tiered dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-tiered dosing of pantoprazole
Study: 38837864
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg total body weight dosing of pantoprazole
Study: 38837864
Drug: 1.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg/kg lean body weight dosing of pantoprazole
Study: 38837864
Drug: FDA-recommended weight-tiered
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA-recommended weight-tiered dosing of pantoprazole
Study: 38838287
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (TKI; sunitinib or cabozantinib)
Study: 38838477
Drug: Phoenix App
Normalized name: Phoenix dactylifera pollen
DrugBank: Phoenix dactylifera pollen (DB10950)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phoenix App + Nicotine Replacement Therapy
Study: 38838500
Drug: Pemigatinib 13.5
Normalized name: pemigatinib 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemigatinib 13.5 mg once daily in 21-day cycles (2 weeks on, 1 week off) until disease progression or unacceptable toxicity.
Study: 38838501
Drug: Nivolumab ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab ± ipilimumab combined with stereotactic radiation therapy
Study: 38839047
Drug: Intravenous remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous remdesivir
Study: 38839101
Drug: Peer comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer comparison antibiotic prescribing feedback (intervention group)
Study: 38839101
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (prolonged duration prescriptions)
Study: 38839252
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of metformin use
Study: 38839505
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg every 3 weeks until disease progression or unacceptable toxicity
Study: 38840086
Drug: Enhanced access
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced access to HPV vaccine + Standard CDC information
Study: 38840086
Drug: Enhanced access
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced access to HPV vaccine + Video narratives
Study: 38840086
Drug: Enhanced access
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced access to HPV vaccine + Written narratives
Study: 38840166
Drug: High baseline
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High baseline CRP (>3 mg/L)
Study: 38840210
Drug: Low inhaled
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low inhaled concentration of desflurane (0.5 MAC) combined with propofol and remifentanil
Study: 38840210
Drug: High inhaled
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High inhaled concentration of desflurane (0.7-1.0 MAC) combined with remifentanil
Study: 38840219
Drug: JAK inhibitors
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAK inhibitors (baricitinib, n=15; tofacitinib, n=10; upadacitinib, n=10)
Study: 38841123
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to daily Occupational Performance (CO-OP) intervention
Study: 38841377
Drug: Reference method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference method (RM) - pill count
Study: 38841781
Drug: Ciprofloxacin 1000
Normalized name: ciprofloxacin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 1000 mg twice daily on D1-D10 + Etoposide 200 mg on D2-D8
Study: 38841781
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg twice daily on D1-D10 + Etoposide 200 mg on D2-D8
Study: 38841799
Drug: Baseline post-bronchodilator
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline post-bronchodilator (post-BD) spirometry measures of lung function
Study: 38842347
Drug: CLN-617 (intratumoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLN-617 (intratumoral injection of a single-chain fusion protein comprising IL2 and IL12)
Study: 38842448
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose DOAC
Study: 38842448
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose DOAC
Study: 38842448
Drug: Low-dose DOAC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose DOAC use
Study: 38842520
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a alone (180 μg per week for 48 weeks)
Study: 38842520
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg bulevirtide plus peginterferon alfa-2a (180 μg per week for 48 weeks)
Study: 38842520
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bulevirtide plus peginterferon alfa-2a (180 μg per week for 48 weeks)
Study: 38842520
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bulevirtide monotherapy (for 96 weeks)
Study: 38842606
Drug: Neoadjuvant-adjuvant anti-PD1
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neoadjuvant-adjuvant anti-PD1 therapy
Study: 38842606
Drug: Adjuvant anti-PD-1
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant anti-PD-1 therapy
Study: 38842606
Drug: Tailored approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored approach to surgery and adjuvant therapy based on response to initial neoadjuvant immunotherapy
Study: 38842738
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied on days 0, 3, 7, and 14 after extraction, repeated biweekly until the end of retraction.
Study: 38842764
Drug: Dexketoprofen 25
Normalized name: dexketoprofen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen 25 mg/vitamin B (thiamine 100 mg, pyridoxine 50 mg, cyanocobalamin 0.50 mg) in a fixed-dose combination (FDC)
Study: 38842764
Drug: Dexketoprofen 25
Normalized name: dexketoprofen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen 25 mg monotherapy